Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC

• DOI: 10.1016/j.jpha.2024.100977
• Publication Date: 2024-04-10T07:10:30Z
• Authors: Feifei Li; Youyang Shi; Mei Ma; Xiaojuan Yang; Xiaosong Chen; Ying Xie; Sheng Liu
• Keywords: Traditional chinese medicine; NK cell; Original Article; ADCC effect; Therapeutics. Pharmacology; RM1-950; Trastuzumab; HER2-positive breast cancer

Trastuzumab has improved survival rates in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), but drug resistance leads to treatment failure. Natural killer (NK) cell-mediated antibody-dependent cell cytotoxicity (ADCC) represents an essential antitumor immune mechanism of trastuzumab. Traditional Chinese medicine (TCM) been used for centuries treat diseases because its capacity improve responses. Xianling Lianxia formula (XLLXF), based on the principle "strengthening body and eliminating toxin", exhibits a synergistic effect trastuzumab patients with HER2-positive BC. Notably, this XLLXF was executed by enhancing NK cells ADCC, as demonstrated through